PYC Therapeutics Advances Polycystic Kidney Disease Drug Candidate to Next Dose Cohort

MT Newswires Live07:24

PYC Therapeutics (ASX:PYC) said that its safety review committee has approved dose escalation to cohort B3 in the ongoing single ascending dose (SAD) trial of PYC-003, following a review of four-week safety data from polycystic kidney disease (PKD) patients in cohorts B1 and B2, according to a Friday Australian bourse filing.

The trial primarily evaluates safety and tolerability, with efficacy as a secondary endpoint, and if successful, will support initiation of a combined phase 2/3 registrational study toward a new drug application for PYC-003, the filing added.

PYC-003 drug candidate is designed to address and treat the underlying cause of PKD, per the filing.

The SAD study will subsequently transition into an open-label multiple ascending dose phase to evaluate repeat dosing and establish the optimal treatment regimen, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614704520?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 07:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614704520","market":"sg","top_or_hot":-1,"title":"PYC Therapeutics Advances Polycystic Kidney Disease Drug Candidate to Next Dose Cohort","media":"MT Newswires Live","content":"<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said that its safety review committee has approved dose escalation to cohort B3 in the ongoing single ascending dose (SAD) trial of PYC-003, following a review of four-week safety data from polycystic kidney disease (PKD) patients in cohorts B1 and B2, according to a Friday Australian bourse filing.</p><p>The trial primarily evaluates safety and tolerability, with efficacy as a secondary endpoint, and if successful, will support initiation of a combined phase 2/3 registrational study toward a new drug application for PYC-003, the filing added.</p><p>PYC-003 drug candidate is designed to address and treat the underlying cause of PKD, per the filing.</p><p>The SAD study will subsequently transition into an open-label multiple ascending dose phase to evaluate repeat dosing and establish the optimal treatment regimen, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PYC Therapeutics Advances Polycystic Kidney Disease Drug Candidate to Next Dose Cohort</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPYC Therapeutics Advances Polycystic Kidney Disease Drug Candidate to Next Dose Cohort\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-27 07:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said that its safety review committee has approved dose escalation to cohort B3 in the ongoing single ascending dose (SAD) trial of PYC-003, following a review of four-week safety data from polycystic kidney disease (PKD) patients in cohorts B1 and B2, according to a Friday Australian bourse filing.</p><p>The trial primarily evaluates safety and tolerability, with efficacy as a secondary endpoint, and if successful, will support initiation of a combined phase 2/3 registrational study toward a new drug application for PYC-003, the filing added.</p><p>PYC-003 drug candidate is designed to address and treat the underlying cause of PKD, per the filing.</p><p>The SAD study will subsequently transition into an open-label multiple ascending dose phase to evaluate repeat dosing and establish the optimal treatment regimen, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614704520","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614704520","pubTimestamp":1772148274,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PYC Therapeutics  said that its safety review committee has approved dose escalation to cohort B3 in the ongoing single ascending dose  trial of PYC-003, following a review of four-week safety data from polycystic kidney disease  patients in cohorts B1 and B2, according to a Friday Australian bourse filing.The trial primarily evaluates safety and tolerability, with efficacy as a secondary endpoint, and if successful, will support initiation of a combined phase 2/3 registrational study toward a new drug application for PYC-003, the filing added.PYC-003 drug candidate is designed to address and treat the underlying cause of PKD, per the filing.The SAD study will subsequently transition into an open-label multiple ascending dose phase to evaluate repeat dosing and establish the optimal treatment regimen, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK7067":"生物科技","BK7047":"环境与设施服务","PYC.AU":"PYC THERAPEUTICS LTD","LENZ":"Therapeutics","BK4007":"制药","BK4539":"次新股","PKD.AU":"PARKD LTD","PKD":"帕克钻井"},"translate_title":"PYC Therapeutics将多囊肾病候选药物推进到下一个剂量队列","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PKD.AU":1,"LENZ":1.5,"PYC.AU":1,"PKD":1},"content_text":"PYC Therapeutics (ASX:PYC) said that its safety review committee has approved dose escalation to cohort B3 in the ongoing single ascending dose (SAD) trial of PYC-003, following a review of four-week safety data from polycystic kidney disease (PKD) patients in cohorts B1 and B2, according to a Friday Australian bourse filing.The trial primarily evaluates safety and tolerability, with efficacy as a secondary endpoint, and if successful, will support initiation of a combined phase 2/3 registrational study toward a new drug application for PYC-003, the filing added.PYC-003 drug candidate is designed to address and treat the underlying cause of PKD, per the filing.The SAD study will subsequently transition into an open-label multiple ascending dose phase to evaluate repeat dosing and establish the optimal treatment regimen, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614704520","isCrawlerRequest":true}